{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T10:21:59Z","timestamp":1743157319026,"version":"3.40.3"},"publisher-location":"Cham","reference-count":96,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030809621"},{"type":"electronic","value":"9783030809621"}],"license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-3-030-80962-1_396-1","type":"book-chapter","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T04:12:47Z","timestamp":1708315967000},"page":"1-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trastuzumab for Active Targeting in Cancer Therapy"],"prefix":"10.1007","author":[{"given":"Ana Camila","family":"Marques","sequence":"first","affiliation":[]},{"given":"Paulo Cardoso","family":"da Costa","sequence":"additional","affiliation":[]},{"given":"S\u00e9rgia","family":"Velho","sequence":"additional","affiliation":[]},{"given":"Maria Helena","family":"Amaral","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"issue":"1","key":"396-1_CR1","doi-asserted-by":"publisher","first-page":"7347","DOI":"10.1038\/s41598-021-86762-6","volume":"11","author":"MR Abedin","year":"2021","unstructured":"Abedin MR, Powers K, Aiardo R, Barua D, Barua S (2021) Antibody-drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells. Sci Rep 11(1):7347. https:\/\/doi.org\/10.1038\/s41598-021-86762-6","journal-title":"Sci Rep"},{"key":"396-1_CR2","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.2147\/ijn.S256898","volume":"15","author":"FS Aleanizy","year":"2020","unstructured":"Aleanizy FS, Alqahtani FY, Seto S, Al Khalil N, Aleshaiwi L, Alghamdi M, Alquadeib B, Alkahtani H, Aldarwesh A, Alqahtani QH, Abdelhady HG, Alsarra I (2020) Trastuzumab targeted Neratinib loaded poly-Amidoamine dendrimer Nanocapsules for breast cancer therapy. Int J Nanomedicine 15:5433\u20135443. https:\/\/doi.org\/10.2147\/ijn.S256898","journal-title":"Int J Nanomedicine"},{"key":"396-1_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.addr.2019.05.010","volume":"143","author":"AM Alkilany","year":"2019","unstructured":"Alkilany AM, Zhu L, Weller H, Mews A, Parak WJ, Barz M, Feliu N (2019) Ligand density on nanoparticles: a parameter with critical impact on nanomedicine. Adv Drug Deliv Rev 143:22\u201336. https:\/\/doi.org\/10.1016\/j.addr.2019.05.010","journal-title":"Adv Drug Deliv Rev"},{"key":"396-1_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jddst.2018.07.017","volume":"47","author":"M Amin","year":"2018","unstructured":"Amin M, Pourshohod A, Kheirollah A, Afrakhteh M, Gholami-Borujeni F, Zeinali M, Jamalan M (2018) Specific delivery of idarubicin to HER2-positive breast cancerous cell line by trastuzumab-conjugated liposomes. J Drug Deliv Sci Technol 47:209\u2013214. https:\/\/doi.org\/10.1016\/j.jddst.2018.07.017","journal-title":"J Drug Deliv Sci Technol"},{"issue":"12","key":"396-1_CR5","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1021\/bc8002452","volume":"19","author":"MG Anhorn","year":"2008","unstructured":"Anhorn MG, Wagner S, Kreuter J, Langer K, von Briesen H (2008) Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. Bioconjug Chem 19(12):2321\u20132331. https:\/\/doi.org\/10.1021\/bc8002452","journal-title":"Bioconjug Chem"},{"issue":"6","key":"396-1_CR6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.nano.2011.03.009","volume":"7","author":"G Arya","year":"2011","unstructured":"Arya G, Vandana M, Acharya S, Sahoo SK (2011) Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy. Nanomedicine 7(6):859\u2013870. https:\/\/doi.org\/10.1016\/j.nano.2011.03.009","journal-title":"Nanomedicine"},{"issue":"5","key":"396-1_CR7","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/jbm.a.34448","volume":"101","author":"RS Ayd\u0131n","year":"2013","unstructured":"Ayd\u0131n RS (2013) Herceptin-decorated salinomycin-loaded nanoparticles for breast tumor targeting. J Biomed Mater Res A 101(5):1405\u20131415. https:\/\/doi.org\/10.1002\/jbm.a.34448","journal-title":"J Biomed Mater Res A"},{"key":"396-1_CR8","doi-asserted-by":"publisher","unstructured":"Baah S, Laws M, Rahman KM (2021) Antibody-drug conjugates \u2013 a tutorial review. Molecules (Basel, Switzerland) 26(10). https:\/\/doi.org\/10.3390\/molecules26102943","DOI":"10.3390\/molecules26102943"},{"key":"396-1_CR9","doi-asserted-by":"publisher","unstructured":"Badkas A, Frank E, Zhou Z, Jafari M, Chandra H, Sriram V, Lee JY, Yadav JS (2018) Modulation of in vitro phagocytic uptake and immunogenicity potential of modified Herceptin\u00ae-conjugated PLGA-PEG nanoparticles for drug delivery. Colloids Surf B Biointerfaces 162:271\u2013278. https:\/\/doi.org\/10.1016\/j.colsurfb.2017.12.001","DOI":"10.1016\/j.colsurfb.2017.12.001"},{"issue":"8","key":"396-1_CR10","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/s1470-2045(19)30328-6","volume":"20","author":"U Banerji","year":"2019","unstructured":"Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P (2019) Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 20(8):1124\u20131135. https:\/\/doi.org\/10.1016\/s1470-2045(19)30328-6","journal-title":"Lancet Oncol"},{"key":"396-1_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbiosy.2021.100032","volume":"5","author":"C Barth","year":"2022","unstructured":"Barth C, Spreen H, Mulac D, Keuter L, Behrens M, Humpf HU, Langer K (2022) Spacer length and serum protein adsorption affect active targeting of trastuzumab-modified nanoparticles. Biomater Biosyst 5:100032. https:\/\/doi.org\/10.1016\/j.bbiosy.2021.100032","journal-title":"Biomater Biosyst"},{"issue":"9","key":"396-1_CR12","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1073\/pnas.1216893110","volume":"110","author":"S Barua","year":"2013","unstructured":"Barua S, Yoo JW, Kolhar P, Wakankar A, Gokarn YR, Mitragotri S (2013) Particle shape enhances specificity of antibody-displaying nanoparticles. Proc Natl Acad Sci U S A 110(9):3270\u20133275. https:\/\/doi.org\/10.1073\/pnas.1216893110","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"396-1_CR13","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1158\/1078-0432.Ccr-15-2499","volume":"22","author":"J Baselga","year":"2016","unstructured":"Baselga J, Lewis Phillips GD, Verma S, Ro J, Huober J, Guardino AE, Samant MK, Olsen S, de Haas SL, Pegram MD (2016) Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of Trastuzumab Emtansine in HER2-positive metastatic breast cancer. Clin Cancer Res 22(15):3755\u20133763. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-2499","journal-title":"Clin Cancer Res"},{"issue":"1","key":"396-1_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10549-013-2667-y","volume":"141","author":"A Catania","year":"2013","unstructured":"Catania A, Barraj\u00f3n-Catal\u00e1n E, Nicolosi S, Cicirata F, Micol V (2013) Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells. Breast Cancer Res Treat 141(1):55\u201365. https:\/\/doi.org\/10.1007\/s10549-013-2667-y","journal-title":"Breast Cancer Res Treat"},{"issue":"10200","key":"396-1_CR15","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/s0140-6736(19)31774-x","volume":"394","author":"CH Chau","year":"2019","unstructured":"Chau CH, Steeg PS, Figg WD (2019) Antibody-drug conjugates for cancer. Lancet 394(10200):793\u2013804. https:\/\/doi.org\/10.1016\/s0140-6736(19)31774-x","journal-title":"Lancet"},{"key":"396-1_CR16","doi-asserted-by":"publisher","unstructured":"Chis AA, Dobrea C, Morgovan C, Arseniu AM, Rus LL, Butuca A, Juncan AM, Totan M, Vonica-Tincu AL, Cormos G, Muntean AC, Muresan ML, Gligor FG, Frum A (2020) Applications and limitations of dendrimers in biomedicine. Molecules (Basel, Switzerland) 25(17). https:\/\/doi.org\/10.3390\/molecules25173982","DOI":"10.3390\/molecules25173982"},{"key":"396-1_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.colsurfb.2017.07.064","volume":"159","author":"JS Choi","year":"2017","unstructured":"Choi JS, Park JS (2017) Surface modification of docetaxel nanocrystals with HER2 antibody to enhance cell growth inhibition in breast cancer cells. Colloids Surf B Biointerfaces 159:139\u2013150. https:\/\/doi.org\/10.1016\/j.colsurfb.2017.07.064","journal-title":"Colloids Surf B Biointerfaces"},{"key":"396-1_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.msec.2018.06.059","volume":"92","author":"JS Choi","year":"2018","unstructured":"Choi JS, Jang WS, Park JS (2018) Comparison of adsorption and conjugation of Herceptin on poly(lactic-co-glycolic acid) nanoparticles - effect on cell internalization in breast cancer cells. Mater Sci Eng C Mater Biol Appl 92:496\u2013507. https:\/\/doi.org\/10.1016\/j.msec.2018.06.059","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"396-1_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nchem.2415","volume":"8","author":"V Chudasama","year":"2016","unstructured":"Chudasama V, Maruani A, Caddick S (2016) Recent advances in the construction of antibody\u2013drug conjugates. Nat Chem 8:114. https:\/\/doi.org\/10.1038\/nchem.2415","journal-title":"Nat Chem"},{"issue":"3","key":"396-1_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.jconrel.2010.02.026","volume":"144","author":"A Cirstoiu-Hapca","year":"2010","unstructured":"Cirstoiu-Hapca A, Buchegger F, Lange N, Bossy L, Gurny R, Delie F (2010) Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: therapeutic efficacy and biodistribution in mice. J Control Release 144(3):324\u2013331. https:\/\/doi.org\/10.1016\/j.jconrel.2010.02.026","journal-title":"J Control Release"},{"issue":"12","key":"396-1_CR21","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA (2022) Trastuzumab Deruxtecan versus Trastuzumab Emtansine for breast cancer. N Engl J Med 386(12):1143\u20131154. https:\/\/doi.org\/10.1056\/NEJMoa2115022","journal-title":"N Engl J Med"},{"key":"396-1_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.colsurfb.2019.03.011","volume":"178","author":"R Dom\u00ednguez-R\u00edos","year":"2019","unstructured":"Dom\u00ednguez-R\u00edos R, S\u00e1nchez-Ram\u00edrez DR, Ruiz-Saray K, Oceguera-Basurto PE, Almada M, Ju\u00e1rez J, Zepeda-Moreno A, del Toro-Arreola A, Topete A, Daneri-Navarro A (2019) Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy. Colloids Surf B Biointerfaces 178:199\u2013207. https:\/\/doi.org\/10.1016\/j.colsurfb.2019.03.011","journal-title":"Colloids Surf B Biointerfaces"},{"key":"396-1_CR23","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.2147\/IJN.S153795","volume":"13","author":"D Duan","year":"2018","unstructured":"Duan D, Wang A, Ni L, Zhang L, Yan X, Jiang Y, Mu H, Wu Z, Sun K, Li Y (2018) Trastuzumab- and Fab' fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo. Int J Nanomedicine 13:1831\u20131840. https:\/\/doi.org\/10.2147\/IJN.S153795","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"396-1_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2174\/1871520616666160526103432","volume":"17","author":"JO Eloy","year":"2017","unstructured":"Eloy JO, Petrilli R, Brueggemeier RW, Marchetti JM, Lee RJ (2017a) Rapamycin-loaded Immunoliposomes functionalized with Trastuzumab: a strategy to enhance cytotoxicity to HER2-positive breast cancer cells. Anti Cancer Agents Med Chem 17(1):48\u201356","journal-title":"Anti Cancer Agents Med Chem"},{"key":"396-1_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ejpb.2017.02.020","volume":"115","author":"JO Eloy","year":"2017","unstructured":"Eloy JO, Petrilli R, Chesca DL, Saggioro FP, Lee RJ, Marchetti JM (2017b) Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy. Eur J Pharm Biopharm 115:159\u2013167. https:\/\/doi.org\/10.1016\/j.ejpb.2017.02.020","journal-title":"Eur J Pharm Biopharm"},{"key":"396-1_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2019.101136","volume":"53","author":"F Fathian Kolahkaj","year":"2019","unstructured":"Fathian Kolahkaj F, Derakhshandeh K, Khaleseh F, Azandaryani AH, Mansouri K, Khazaei M (2019) Active targeting carrier for breast cancer treatment: monoclonal antibody conjugated epirubicin loaded nanoparticle. J Drug Deliv Sci Technol 53:101136. https:\/\/doi.org\/10.1016\/j.jddst.2019.101136","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"396-1_CR27","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1080\/10717544.2020.1837294","volume":"27","author":"Q Fu","year":"2020","unstructured":"Fu Q, Wang J, Liu H (2020) Chemo-immune synergetic therapy of esophageal carcinoma: trastuzumab modified, cisplatin and fluorouracil co-delivered lipid-polymer hybrid nanoparticles. Drug Deliv 27(1):1535\u20131543. https:\/\/doi.org\/10.1080\/10717544.2020.1837294","journal-title":"Drug Deliv"},{"key":"396-1_CR28","doi-asserted-by":"publisher","unstructured":"Goto K, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, Ahn MJ, Smit EF, de Langen AJ, P\u00e9rol M, Pons-Tostivint E, Novello S, Hayashi H, Shimizu J, Kim DW, Kuo CH, Yang JC, Pereira K, Cheng FC, Taguchi A, Cheng Y, Feng W, Tsuchihashi Z, J\u00e4nne PA (2023) Trastuzumab Deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial. J Clin Oncol:Jco2301361. https:\/\/doi.org\/10.1200\/jco.23.01361","DOI":"10.1200\/jco.23.01361"},{"issue":"1","key":"396-1_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1039\/C7SC02747H","volume":"9","author":"MK Greene","year":"2018","unstructured":"Greene MK, Richards DA, Nogueira JCF, Campbell K, Smyth P, Fern\u00e1ndez M, Scott CJ, Chudasama V (2018) Forming next-generation antibody\u2013nanoparticle conjugates through the oriented installation of non-engineered antibody fragments. Chem Sci 9(1):79\u201387. https:\/\/doi.org\/10.1039\/C7SC02747H","journal-title":"Chem Sci"},{"issue":"6","key":"396-1_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198141","volume":"13","author":"S Gu","year":"2018","unstructured":"Gu S, Ngamcherdtrakul W, Reda M, Hu Z, Gray JW, Yantasee W (2018) Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment. PLoS One 13(6):e0198141. https:\/\/doi.org\/10.1371\/journal.pone.0198141","journal-title":"PLoS One"},{"key":"396-1_CR31","doi-asserted-by":"publisher","unstructured":"Houdaihed L, Evans JC, Allen C (2019) In vivo evaluation of dual-targeted nanoparticles encapsulating paclitaxel and Everolimus. Cancers 11(6). https:\/\/doi.org\/10.3390\/cancers11060752","DOI":"10.3390\/cancers11060752"},{"issue":"6","key":"396-1_CR32","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1159\/000485955","volume":"44","author":"N Hu","year":"2017","unstructured":"Hu N, Yin JF, Ji Z, Hong Y, Wu P, Bian B, Song Z, Li R, Liu Q, Wu F (2017) Strengthening gastric cancer therapy by Trastuzumab-conjugated nanoparticles with simultaneous encapsulation of anti-MiR-21 and 5-Fluorouridine. Cell Physiol Biochem 44(6):2158\u20132173. https:\/\/doi.org\/10.1159\/000485955","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"396-1_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA (2007) Trastuzumab \u2013 mechanism of action and use in clinical practice. N Engl J Med 357(1):39\u201351. https:\/\/doi.org\/10.1056\/NEJMra043186","journal-title":"N Engl J Med"},{"issue":"1","key":"396-1_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/btm2.10122","volume":"4","author":"M Jarvis","year":"2019","unstructured":"Jarvis M, Krishnan V, Mitragotri S (2019) Nanocrystals: a perspective on translational research and clinical studies. Bioeng Transl Med 4(1):5\u201316. https:\/\/doi.org\/10.1002\/btm2.10122","journal-title":"Bioeng Transl Med"},{"key":"396-1_CR35","doi-asserted-by":"publisher","unstructured":"Juan A, Cimas FJ, Bravo I, Pandiella A, Oca\u00f1a A, Alonso-Moreno C (2020) Antibody conjugation of nanoparticles as therapeutics for breast cancer treatment. Int J Mol Sci 21(17). https:\/\/doi.org\/10.3390\/ijms21176018","DOI":"10.3390\/ijms21176018"},{"issue":"3","key":"396-1_CR36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1049\/nbt2.12012","volume":"15","author":"F Khaleseh","year":"2021","unstructured":"Khaleseh F, Hemmati Azandaryani A, Fathian Kolahkaj F, Khazaei M, Derakhshandeh K (2021) Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation. IET Nanobiotechnol 15(3):257\u2013265. https:\/\/doi.org\/10.1049\/nbt2.12012","journal-title":"IET Nanobiotechnol"},{"key":"396-1_CR102","doi-asserted-by":"publisher","unstructured":"Khetan R, Dharmayanti C, Gillam TA, K\u00fcbler E, Klingler-Hoffmann M, Ricciardelli C, Oehler MK, Blencowe A, Garg S, Albrecht H (2022) Using GPCRs as molecular beacons to target ovarian cancer with nanomedicines. Cancers 14(10). https:\/\/doi.org\/10.3390\/cancers14102362","DOI":"10.3390\/cancers14102362"},{"key":"396-1_CR37","doi-asserted-by":"publisher","unstructured":"Kondrashov A, Sapkota S, Sharma A, Riano I, Kurzrock R, Adashek JJ (2023) Antibody-drug conjugates in solid tumor oncology: an effectiveness payday with a targeted payload. Pharmaceutics 15(8). https:\/\/doi.org\/10.3390\/pharmaceutics15082160","DOI":"10.3390\/pharmaceutics15082160"},{"key":"396-1_CR38","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.2147\/ijn.S23211","volume":"6","author":"MN Koopaei","year":"2011","unstructured":"Koopaei MN, Dinarvand R, Amini M, Rabbani H, Emami S, Ostad SN, Atyabi F (2011) Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies. Int J Nanomedicine 6:1903\u20131912. https:\/\/doi.org\/10.2147\/ijn.S23211","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"396-1_CR39","doi-asserted-by":"publisher","first-page":"23179","DOI":"10.1038\/srep23179","volume":"6","author":"H Kulhari","year":"2016","unstructured":"Kulhari H, Pooja D, Shrivastava S, Kuncha M, Naidu VGM, Bansal V, Sistla R, Adams DJ (2016) Trastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer. Sci Rep 6(1):23179. https:\/\/doi.org\/10.1038\/srep23179","journal-title":"Sci Rep"},{"issue":"7","key":"396-1_CR40","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1021\/mp300049n","volume":"9","author":"M Kullberg","year":"2012","unstructured":"Kullberg M, Mann K, Anchordoquy TJ (2012) Targeting her-2+ breast cancer cells with Bleomycin Immunoliposomes linked to LLO. Mol Pharm 9(7):2000\u20132008. https:\/\/doi.org\/10.1021\/mp300049n","journal-title":"Mol Pharm"},{"key":"396-1_CR41","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.colsurfb.2018.10.007","volume":"173","author":"A Kumar Mehata","year":"2019","unstructured":"Kumar Mehata A, Bharti S, Singh P, Viswanadh MK, Kumari L, Agrawal P, Singh S, Koch B, Muthu MS (2019) Trastuzumab decorated TPGS-g-chitosan nanoparticles for targeted breast cancer therapy. Colloids Surf B Biointerfaces 173:366\u2013377. https:\/\/doi.org\/10.1016\/j.colsurfb.2018.10.007","journal-title":"Colloids Surf B Biointerfaces"},{"key":"396-1_CR42","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.colsurfb.2016.10.044","volume":"149","author":"A Kumar","year":"2017","unstructured":"Kumar A, Lale SV, Aji Alex MR, Choudhary V, Koul V (2017) Folic acid and trastuzumab conjugated redox responsive random multiblock copolymeric nanocarriers for breast cancer therapy: in-vitro and in-vivo studies. Colloids Surf B Biointerfaces 149:369\u2013378. https:\/\/doi.org\/10.1016\/j.colsurfb.2016.10.044","journal-title":"Colloids Surf B Biointerfaces"},{"key":"396-1_CR104","doi-asserted-by":"publisher","unstructured":"Langer K, Anhorn MG, Steinhauser I, Dreis S, Celebi D, Schrickel N, Faust S, Vogel V (2008) Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation. Int J Pharm 347(1\u20132):109\u2013117. https:\/\/doi.org\/10.1016\/j.ijpharm.2007.06.028","DOI":"10.1016\/j.ijpharm.2007.06.028"},{"issue":"3","key":"396-1_CR43","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/bf02256453","volume":"10","author":"CH Lee","year":"2003","unstructured":"Lee CH, Hsiao M, Tseng YL, Chang FH (2003) Enhanced gene delivery to HER-2-overexpressing breast cancer cells by modified immunolipoplexes conjugated with the anti-HER-2 antibody. J Biomed Sci 10(3):337\u2013344. https:\/\/doi.org\/10.1007\/bf02256453","journal-title":"J Biomed Sci"},{"issue":"3","key":"396-1_CR45","first-page":"1255","volume":"11","author":"N Li","year":"2019","unstructured":"Li N, Xie X, Hu Y, He H, Fu X, Fang T, Li C (2019) Herceptin-conjugated liposomes co-loaded with doxorubicin and simvastatin in targeted prostate cancer therapy. Am J Transl Res 11(3):1255\u20131269","journal-title":"Am J Transl Res"},{"issue":"3","key":"396-1_CR46","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1021\/acs.molpharmaceut.0c01090","volume":"18","author":"M Li","year":"2021","unstructured":"Li M, Dong J, Cheng F, Li C, Wang H, Sun T, He W, Wang Q (2021) Controlling conjugated antibodies at the molecular level for active targeting nanoparticles toward HER2-positive cancer cells. Mol Pharm 18(3):1196\u20131207. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c01090","journal-title":"Mol Pharm"},{"issue":"3","key":"396-1_CR47","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","volume":"386","author":"BT Li","year":"2022","unstructured":"Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazi\u00e8res J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, P\u00e9rol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, J\u00e4nne PA (2022) Trastuzumab Deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med 386(3):241\u2013251. https:\/\/doi.org\/10.1056\/NEJMoa2112431","journal-title":"N Engl J Med"},{"issue":"35","key":"396-1_CR48","doi-asserted-by":"publisher","first-page":"9145","DOI":"10.1016\/j.biomaterials.2010.08.053","volume":"31","author":"Y Liu","year":"2010","unstructured":"Liu Y, Li K, Liu B, Feng SS (2010) A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials 31(35):9145\u20139155. https:\/\/doi.org\/10.1016\/j.biomaterials.2010.08.053","journal-title":"Biomaterials"},{"key":"396-1_CR49","doi-asserted-by":"publisher","unstructured":"Luo F, Zhong T, Chen Y, Guo Q, Tao L, Shen X, Fan Y, Wu X (2023) Dual-ligand synergistic targeting anti-tumor Nanoplatforms with Cascade-responsive drug release. Pharmaceutics 15(7). https:\/\/doi.org\/10.3390\/pharmaceutics15072014","DOI":"10.3390\/pharmaceutics15072014"},{"key":"396-1_CR100","doi-asserted-by":"publisher","unstructured":"Maadi H, Soheilifar MH, Choi WS, Moshtaghian A, Wang Z (2021) Trastuzumab mechanism of action; 20 years of research to unravel a dilemma. Cancers 13(14). https:\/\/doi.org\/10.3390\/cancers13143540","DOI":"10.3390\/cancers13143540"},{"key":"396-1_CR50","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jconrel.2020.01.035","volume":"320","author":"AC Marques","year":"2020","unstructured":"Marques AC, Costa PJ, Velho S, Amaral MH (2020) Functionalizing nanoparticles with cancer-targeting antibodies: a comparison of strategies. J Control Release 320:180\u2013200. https:\/\/doi.org\/10.1016\/j.jconrel.2020.01.035","journal-title":"J Control Release"},{"key":"396-1_CR51","doi-asserted-by":"publisher","unstructured":"Marques AC, Costa PC, Velho S, Amaral MH (2023) Lipid nanoparticles functionalized with antibodies for anticancer drug therapy. Pharmaceutics 15(1). https:\/\/doi.org\/10.3390\/pharmaceutics15010216","DOI":"10.3390\/pharmaceutics15010216"},{"key":"396-1_CR52","doi-asserted-by":"publisher","unstructured":"Matusewicz L, Podkalicka J, Sikorski AF (2018) Immunoliposomes with simvastatin as a potential therapeutic in treatment of breast cancer cells overexpressing HER2-an in vitro study. Cancers 10(11). https:\/\/doi.org\/10.3390\/cancers10110418","DOI":"10.3390\/cancers10110418"},{"issue":"sup3","key":"396-1_CR53","doi-asserted-by":"publisher","first-page":"S556","DOI":"10.1080\/21691401.2018.1501380","volume":"46","author":"LX Meng","year":"2018","unstructured":"Meng LX, Ren Q, Meng Q, Zheng YX, He ML, Sun SY, Ding ZJ, Li BC, Wang HY (2018) Trastuzumab modified silica nanoparticles loaded with doxorubicin for targeted and synergic therapy of breast cancer. Artif Cells Nanomed Biotechnol 46(sup3):S556\u2013s563. https:\/\/doi.org\/10.1080\/21691401.2018.1501380","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"396-1_CR54","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12885-016-2385-z","volume":"16","author":"K Miller","year":"2016","unstructured":"Miller K, Cortes J, Hurvitz SA, Krop IE, Tripathy D, Verma S, Riahi K, Reynolds JG, Wickham TJ, Molnar I, Yardley DA (2016) HERMIONE: a randomized phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-na\u00efve, HER2-positive, locally advanced\/metastatic breast cancer. BMC Cancer 16:352. https:\/\/doi.org\/10.1186\/s12885-016-2385-z","journal-title":"BMC Cancer"},{"issue":"7","key":"396-1_CR55","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I (2020) Trastuzumab Deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 382(7):610\u2013621. https:\/\/doi.org\/10.1056\/NEJMoa1914510","journal-title":"N Engl J Med"},{"issue":"1","key":"396-1_CR56","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA (2022) Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387(1):9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690","journal-title":"N Engl J Med"},{"key":"396-1_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.micromeso.2021.110950","volume":"316","author":"M Mozafarinia","year":"2021","unstructured":"Mozafarinia M, Karimi S, Farrokhnia M, Esfandiari J (2021) In vitro breast cancer targeting using Trastuzumab-conjugated mesoporous silica nanoparticles: towards the new strategy for decreasing size and high drug loading capacity for drug delivery purposes in MSN synthesis. Microporous Mesoporous Mat 316:110950. https:\/\/doi.org\/10.1016\/j.micromeso.2021.110950","journal-title":"Microporous Mesoporous Mat"},{"issue":"9","key":"396-1_CR58","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41416-018-0235-2","volume":"119","author":"P Munster","year":"2018","unstructured":"Munster P, Krop IE, LoRusso P, Ma C, Siegel BA, Shields AF, Moln\u00e1r I, Wickham TJ, Reynolds J, Campbell K, Hendriks BS, Adiwijaya BS, Geretti E, Moyo V, Miller KD (2018) Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. Br J Cancer 119(9):1086\u20131093. https:\/\/doi.org\/10.1038\/s41416-018-0235-2","journal-title":"Br J Cancer"},{"key":"396-1_CR59","doi-asserted-by":"publisher","unstructured":"Nadal-Serrano M, Morancho B, Escriv\u00e1-de-Roman\u00ed S, Morales CB, Luque A, Escorihuela M, Espinosa Bravo M, Peg V, Dijcks FA, Dokter WHA, Cort\u00e9s J, Saura C, Arribas J (2020) The second generation antibody-drug conjugate SYD985 overcomes resistances to T-DM1. Cancers 12(3). https:\/\/doi.org\/10.3390\/cancers12030670","DOI":"10.3390\/cancers12030670"},{"issue":"11","key":"396-1_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202107550","volume":"18","author":"W Ngamcherdtrakul","year":"2022","unstructured":"Ngamcherdtrakul W, Bejan DS, Cruz-Mu\u00f1oz W, Reda M, Zaidan HY, Siriwon N, Marshall S, Wang R, Nelson MA, Rehwaldt JPC, Gray JW, Hynynen K, Yantasee W (2022) Targeted nanoparticle for co-delivery of HER2 siRNA and a Taxane to Mirror the standard treatment of HER2+ breast cancer: efficacy in breast tumor and brain metastasis. Small 18(11):e2107550. https:\/\/doi.org\/10.1002\/smll.202107550","journal-title":"Small"},{"key":"396-1_CR61","doi-asserted-by":"publisher","unstructured":"Nieto C, Vega MA, Mart\u00edn Del Valle EM (2020) Trastuzumab: more than a guide in HER2-positive cancer Nanomedicine. Nano 10(9). https:\/\/doi.org\/10.3390\/nano10091674","DOI":"10.3390\/nano10091674"},{"key":"396-1_CR62","doi-asserted-by":"publisher","unstructured":"Niza E, Noblejas-L\u00f3pez MDM, Bravo I, Nieto-Jim\u00e9nez C, Castro-Osma JA, Canales-V\u00e1zquez J, Lara-Sanchez A, Gal\u00e1n Moya EM, Burgos M, Oca\u00f1a A, Alonso-Moreno C (2019) Trastuzumab-targeted biodegradable nanoparticles for enhanced delivery of Dasatinib in HER2+ Metastasic breast cancer. Nano 9(12). https:\/\/doi.org\/10.3390\/nano9121793","DOI":"10.3390\/nano9121793"},{"issue":"1\u20132","key":"396-1_CR63","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ijpharm.2016.09.067","volume":"513","author":"JK Noh","year":"2016","unstructured":"Noh JK, Naeem M, Cao J, Lee EH, Kim MS, Jung Y, Yoo JW (2016) Herceptin-functionalized pure paclitaxel nanocrystals for enhanced delivery to HER2-postive breast cancer cells. Int J Pharm 513(1\u20132):543\u2013553. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.09.067","journal-title":"Int J Pharm"},{"key":"396-1_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119420","volume":"222","author":"J Peng","year":"2019","unstructured":"Peng J, Chen J, Xie F, Bao W, Xu H, Wang H, Xu Y, Du Z (2019) Herceptin-conjugated paclitaxel loaded PCL-PEG worm-like nanocrystal micelles for the combinatorial treatment of HER2-positive breast cancer. Biomaterials 222:119420. https:\/\/doi.org\/10.1016\/j.biomaterials.2019.119420","journal-title":"Biomaterials"},{"issue":"6","key":"396-1_CR65","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1517\/17425247.2013.777425","volume":"10","author":"A Raju","year":"2013","unstructured":"Raju A, Muthu MS, Feng SS (2013) Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel. Expert Opin Drug Deliv 10(6):747\u2013760. https:\/\/doi.org\/10.1517\/17425247.2013.777425","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"396-1_CR66","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1038\/s41598-020-60856-z","volume":"10","author":"A Rodallec","year":"2020","unstructured":"Rodallec A, Franco C, Robert S, Sicard G, Giacometti S, Lacarelle B, Bouquet F, Savina A, Lacroix R, Dignat-George F, Ciccolini J, Poncelet P, Fanciullino R (2020a) Prototyping Trastuzumab docetaxel Immunoliposomes with a new FCM-based method to quantify optimal antibody density on nanoparticles. Sci Rep 10(1):4147. https:\/\/doi.org\/10.1038\/s41598-020-60856-z","journal-title":"Sci Rep"},{"issue":"5","key":"396-1_CR67","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/cad.0000000000000878","volume":"31","author":"A Rodallec","year":"2020","unstructured":"Rodallec A, Sicard G, Giacometti S, Carre M, Maia T, Valette M, Bouquet F, Savina A, Lacarelle B, Ciccolini J, Fanciullino R (2020b) Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3). Anti-Cancer Drugs 31(5):463\u2013472. https:\/\/doi.org\/10.1097\/cad.0000000000000878","journal-title":"Anti-Cancer Drugs"},{"key":"396-1_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.855294","volume":"13","author":"M Sakhi","year":"2022","unstructured":"Sakhi M, Khan A, Iqbal Z, Khan I, Raza A, Ullah A, Nasir F, Khan SA (2022) Design and characterization of paclitaxel-loaded polymeric nanoparticles decorated with Trastuzumab for the effective treatment of breast cancer. Front Pharmacol 13:855294. https:\/\/doi.org\/10.3389\/fphar.2022.855294","journal-title":"Front Pharmacol"},{"key":"396-1_CR69","doi-asserted-by":"publisher","unstructured":"Saravanakumar K, Sathiyaseelan A, Park S, Kim SR, Priya VV, Wang MH (2022) Monoclonal antibody functionalized, and L-lysine \u03b1-oxidase loaded PEGylated-chitosan nanoparticle for HER2\/Neu targeted breast cancer therapy. Pharmaceutics 14(5). https:\/\/doi.org\/10.3390\/pharmaceutics14050927","DOI":"10.3390\/pharmaceutics14050927"},{"key":"396-1_CR70","doi-asserted-by":"crossref","unstructured":"Saura Manich C, O'Shaughnessy J, Aftimos PG, van den Tweel E, Oesterholt M, Escriv\u00e1-de-Roman\u00ed SI, Quenel Tueux N, Tan TJ, Lim JS, Ladoire S, Armstrong A, Crook T, Stradella A, Bianchi G, Mulder R, Koper N, Turner N (2021) LBA15 \u2013 primary outcome of the phase III SYD985.002\/TULIP trial comparing [Vic-]trastuzumab duocarmazine to physician\u2019s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. Paper presented at the ESMO congress 2021","DOI":"10.1016\/j.annonc.2021.08.2088"},{"issue":"25","key":"396-1_CR71","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K (2020) Trastuzumab Deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 382(25):2419\u20132430. https:\/\/doi.org\/10.1056\/NEJMoa2004413","journal-title":"N Engl J Med"},{"issue":"4","key":"396-1_CR72","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.nantod.2014.06.002","volume":"9","author":"S Son","year":"2014","unstructured":"Son S, Min HS, You DG, Kim BS, Kwon IC (2014) Echogenic nanoparticles for ultrasound technologies: evolution from diagnostic imaging modality to multimodal theranostic agent. Nano Today 9(4):525\u2013540. https:\/\/doi.org\/10.1016\/j.nantod.2014.06.002","journal-title":"Nano Today"},{"issue":"3","key":"396-1_CR73","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1593\/neo.07916","volume":"10","author":"B Sp\u00e4nkuch","year":"2008","unstructured":"Sp\u00e4nkuch B, Steinhauser I, Wartlick H, Kurunci-Csacsko E, Strebhardt KI, Langer K (2008) Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles. Neoplasia 10(3):223\u2013234. https:\/\/doi.org\/10.1593\/neo.07916","journal-title":"Neoplasia"},{"issue":"29","key":"396-1_CR74","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1016\/j.biomaterials.2008.07.001","volume":"29","author":"IM Steinhauser","year":"2008","unstructured":"Steinhauser IM, Langer K, Strebhardt KM, Sp\u00e4nkuch B (2008) Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation. Biomaterials 29(29):4022\u20134028. https:\/\/doi.org\/10.1016\/j.biomaterials.2008.07.001","journal-title":"Biomaterials"},{"issue":"9","key":"396-1_CR75","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1039\/C9BM01764J","volume":"8","author":"B Sumer Bolu","year":"2020","unstructured":"Sumer Bolu B, Golba B, Sanyal A, Sanyal R (2020) Trastuzumab targeted micellar delivery of docetaxel using dendron\u2013polymer conjugates. Biomater Sci 8(9):2600\u20132610. https:\/\/doi.org\/10.1039\/C9BM01764J","journal-title":"Biomater Sci"},{"issue":"4","key":"396-1_CR76","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2217\/nnm.09.17","volume":"4","author":"B Sun","year":"2009","unstructured":"Sun B, Feng SS (2009) Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel. Nanomedicine (Lond) 4(4):431\u2013445. https:\/\/doi.org\/10.2217\/nnm.09.17","journal-title":"Nanomedicine (Lond)"},{"issue":"4","key":"396-1_CR77","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.biomaterials.2007.09.038","volume":"29","author":"B Sun","year":"2008","unstructured":"Sun B, Ranganathan B, Feng SS (2008) Multifunctional poly(D,L-lactide-co-glycolide)\/montmorillonite (PLGA\/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 29(4):475\u2013486. https:\/\/doi.org\/10.1016\/j.biomaterials.2007.09.038","journal-title":"Biomaterials"},{"issue":"1","key":"396-1_CR78","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2217\/nnm.13.191","volume":"9","author":"R Toy","year":"2014","unstructured":"Toy R, Peiris PM, Ghaghada KB, Karathanasis E (2014) Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine (Lond) 9(1):121\u2013134. https:\/\/doi.org\/10.2217\/nnm.13.191","journal-title":"Nanomedicine (Lond)"},{"key":"396-1_CR101","doi-asserted-by":"publisher","unstructured":"Van Epps HA, Senter PD (2019) Breaking up is hard to do. Nat Chem Biol 15(10):934\u2013935. https:\/\/doi.org\/10.1038\/s41589-019-0351-1","DOI":"10.1038\/s41589-019-0351-1"},{"issue":"4","key":"396-1_CR79","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/08982104.2017.1370471","volume":"28","author":"J Varshosaz","year":"2018","unstructured":"Varshosaz J, Davoudi MA, Rasoul-Amini S (2018) Docetaxel-loaded nanostructured lipid carriers functionalized with trastuzumab (Herceptin) for HER2-positive breast cancer cells. J Liposome Res 28(4):285\u2013295. https:\/\/doi.org\/10.1080\/08982104.2017.1370471","journal-title":"J Liposome Res"},{"issue":"8","key":"396-1_CR80","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1049\/iet-nbt.2018.5363","volume":"13","author":"J Varshosaz","year":"2019","unstructured":"Varshosaz J, Ghassami E, Noorbakhsh A, Minaiyan M, Jahanian-Najafabadi A (2019) Trastuzumab-conjugated nanoparticles composed of poly(butylene adipate-co-butylene terephthalate) prepared by electrospraying technique for targeted delivery of docetaxel. IET Nanobiotechnol 13(8):829\u2013833. https:\/\/doi.org\/10.1049\/iet-nbt.2018.5363","journal-title":"IET Nanobiotechnol"},{"issue":"19","key":"396-1_CR81","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Di\u00e9ras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783\u20131791. https:\/\/doi.org\/10.1056\/NEJMoa1209124","journal-title":"N Engl J Med"},{"issue":"7","key":"396-1_CR82","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, W\u00fclfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr (2019) Trastuzumab Emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380(7):617\u2013628. https:\/\/doi.org\/10.1056\/NEJMoa1814017","journal-title":"N Engl J Med"},{"issue":"40","key":"396-1_CR83","doi-asserted-by":"publisher","first-page":"67189","DOI":"10.18632\/oncotarget.18066","volume":"8","author":"FL Wu","year":"2017","unstructured":"Wu FL, Zhang J, Li W, Bian BX, Hong YD, Song ZY, Wang HY, Cui FB, Li RT, Liu Q, Jiang XD, Li XM, Zheng JN (2017) Enhanced antiproliferative activity of antibody-functionalized polymeric nanoparticles for targeted delivery of anti-miR-21 to HER2 positive gastric cancer. Oncotarget 8(40):67189\u201367202. https:\/\/doi.org\/10.18632\/oncotarget.18066","journal-title":"Oncotarget"},{"issue":"26","key":"396-1_CR84","doi-asserted-by":"publisher","first-page":"8982","DOI":"10.1039\/C7NR01020F","volume":"9","author":"Q Xia","year":"2017","unstructured":"Xia Q, Ding H, Ma Y (2017) Can dual-ligand targeting enhance cellular uptake of nanoparticles? Nanoscale 9(26):8982\u20138989. https:\/\/doi.org\/10.1039\/C7NR01020F","journal-title":"Nanoscale"},{"issue":"3","key":"396-1_CR85","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.3892\/or.2018.6201","volume":"39","author":"J Xiong","year":"2018","unstructured":"Xiong J, Han S, Ding S, He J, Zhang H (2018) Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2-positive gastric cancer. Oncol Rep 39(3):1396\u20131404. https:\/\/doi.org\/10.3892\/or.2018.6201","journal-title":"Oncol Rep"},{"key":"396-1_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.polymertesting.2022.107669","volume":"113","author":"R Xu","year":"2022","unstructured":"Xu R, Sui J, Zhao M, Yang Y, Tong L, Liu Y, Sun Y, Fan Y, Liang J, Zhang X (2022) Targeted inhibition of HER-2 positive breast cancer cells by trastuzumab functionalized pullulan-doxorubicin nanoparticles. Polym Test 113:107669. https:\/\/doi.org\/10.1016\/j.polymertesting.2022.107669","journal-title":"Polym Test"},{"key":"396-1_CR87","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.2147\/ijn.S21523","volume":"6","author":"P Yousefpour","year":"2011","unstructured":"Yousefpour P, Atyabi F, Vasheghani-Farahani E, Movahedi AA, Dinarvand R (2011) Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab. Int J Nanomedicine 6:1977\u20131990. https:\/\/doi.org\/10.2147\/ijn.S21523","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"396-1_CR88","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ijpharm.2015.11.033","volume":"497","author":"K Yu","year":"2016","unstructured":"Yu K, Zhao J, Zhang Z, Gao Y, Zhou Y, Teng L, Li Y (2016) Enhanced delivery of paclitaxel using electrostatically-conjugated Herceptin-bearing PEI\/PLGA nanoparticles against HER-positive breast cancer cells. Int J Pharm 497(1):78\u201387. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.11.033","journal-title":"Int J Pharm"},{"issue":"3","key":"396-1_CR89","doi-asserted-by":"publisher","first-page":"155932581987258","DOI":"10.1177\/1559325819872583","volume":"17","author":"X Zhang","year":"2019","unstructured":"Zhang X, Liu J, Li X, Li F, Lee RJ, Sun F, Li Y, Liu Z, Teng L (2019) Trastuzumab-coated nanoparticles loaded with docetaxel for breast cancer therapy. Dose Response 17(3):1559325819872583. https:\/\/doi.org\/10.1177\/1559325819872583","journal-title":"Dose Response"},{"issue":"10","key":"396-1_CR90","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1016\/j.biomaterials.2014.01.003","volume":"35","author":"J Zhao","year":"2014","unstructured":"Zhao J, Feng SS (2014) Effects of PEG tethering chain length of vitamin E TPGS with a Herceptin-functionalized nanoparticle formulation for targeted delivery of anticancer drugs. Biomaterials 35(10):3340\u20133347. https:\/\/doi.org\/10.1016\/j.biomaterials.2014.01.003","journal-title":"Biomaterials"},{"issue":"4","key":"396-1_CR91","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1080\/10837450.2019.1709500","volume":"25","author":"S Zhong","year":"2020","unstructured":"Zhong S, Ling Z, Zhou Z, He J, Ran H, Wang Z, Zhang Q, Song W, Zhang Y, Luo J (2020) Herceptin-decorated paclitaxel-loaded poly(lactide-co-glycolide) nanobubbles: ultrasound-facilitated release and targeted accumulation in breast cancers. Pharm Dev Technol 25(4):454\u2013463. https:\/\/doi.org\/10.1080\/10837450.2019.1709500","journal-title":"Pharm Dev Technol"},{"issue":"1\u20132","key":"396-1_CR92","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ijpharm.2015.03.081","volume":"487","author":"Z Zhou","year":"2015","unstructured":"Zhou Z, Badkas A, Stevenson M, Lee JY, Leung YK (2015) Herceptin conjugated PLGA-PHis-PEG pH sensitive nanoparticles for targeted and controlled drug delivery. Int J Pharm 487(1\u20132):81\u201390. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.03.081","journal-title":"Int J Pharm"},{"key":"396-1_CR103","doi-asserted-by":"publisher","unstructured":"Zieli\u0144ska M, Zarankiewicz N, Kosz K, Kuchnicka A, Cise\u0142 B (2020) HER2-positive breast cancer \u2013 available anti-HER2 therapies and new agents under investigation. J Pre Clin Clin Res 14(2):44\u201348. https:\/\/doi.org\/10.26444\/jpccr\/122068","DOI":"10.26444\/jpccr\/122068"}],"container-title":["Handbook of Cancer and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-80962-1_396-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T04:13:27Z","timestamp":1708316007000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-80962-1_396-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"ISBN":["9783030809621","9783030809621"],"references-count":96,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-80962-1_396-1","relation":{},"subject":[],"published":{"date-parts":[[2023,11,16]]},"assertion":[{"value":"30 September 2023, 00:00:00","order":1,"name":"received","label":"Received","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"1 October 2023, 00:00:00","order":2,"name":"accepted","label":"Accepted","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"16 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}